TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01745887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-2
Description: The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-2
Description: The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
Study: NCT00574769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Docetaxel, Bevacizumab
Description: RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days
Study: NCT03744286

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slip Training
Description: -On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
Study: NCT02539368

Intervention type: DRUG
Intervention: CT-P13
Description: biosimilar infliximab

Intervention type: DRUG
Intervention: Remicade
Description: infliximab
Study: NCT01570231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilateral limb ischemic preconditioning (Doctormate, IPC-906X)
Description: Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
Study: NCT02647437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT05126498

Intervention type: OTHER
Intervention: no intervention
Description: no intervention was applied
Study: NCT04910165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
Study: NCT01269437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide dry powder inhaler
Description: 200mcg per inhalation, twice daily, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide dry powder inhaler
Description: 200mcg per inhalation, twice daily, for 12 weeks
Study: NCT01821014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person physician interaction
Description: Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
Study: NCT05126498

Intervention type: OTHER
Intervention: no intervention
Description: no intervention was applied

Intervention type: OTHER
Intervention: no intervention
Description: no intervention was applied
Study: NCT01821014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person physician interaction
Description: Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
Study: NCT00273910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)
Study: NCT01821014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person physician interaction
Description: Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
Study: NCT00087035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Will be taken at a starting daily dose of 150mg
Study: NCT03898973

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Quadrivalent inactivated influenza vaccine (IIV)
Description: Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
Study: NCT01415687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol-Based Lavage
Description: Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pico-Salax (Magnesium Citrate) plus Bisacodyl
Description: If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre.
Study: NCT02913326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study: NCT02913326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study: NCT00474357

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Structured Psychoeducation Group Therapy
Description: weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
Study: NCT00273910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)
Study: NCT04126174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femtosecond laser system arcuate corneal incision
Description: Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
Study: NCT00273910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
Study: NCT00910988

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: olanzapine/Zyprexa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: olanzapine/Zyprexa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ziprasidone
Description: ziprasidone/Geodon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: ziprasidone/Geodon
Study: NCT01428362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-1121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-1121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00003800

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: radionuclide imaging
Study: NCT03004443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
Study: NCT02090114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
Study: NCT03742336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Single oral 200 mg dose of PF-04965842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: Single oral 200 mg dose of PF-04965842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Single 75 mg dose of dabigatran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Single 75 mg dose of dabigatran
Study: NCT03222479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress guide
Description: smartphone-based application that can evaluate stress level and teach how to manage their stress
Study: NCT03604471

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Blood sampling for atorvastatin quantification and pharmacogenetic analysis.
Study: NCT04532463

Intervention type: DRUG
Intervention: Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
Description: To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
Study: NCT03004443

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution will be administered intravenously over a 2 to 2.5 hour period.
Study: NCT04126174

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual LRI
Description: Manual LRI
Study: NCT03366831

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thirty Million Words Initiative Newborn Intervention
Description: The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thirty Million Words Initiative Newborn Intervention
Description: The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thirty Million Words Initiative Newborn Intervention
Description: The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thirty Million Words Initiative Newborn Intervention
Description: The Thirty Million Words Initiative Newborn Intervention (TMW-Newborn) is a public health effort aimed at increasing awareness about the importance of a child's early language environment in his or her first years of life. This one-time educational intervention will be impacting maternal awareness and knowledge about the importance of children's early language environment, between ages 0 and 3.
Study: NCT04007731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DrRip - high protein, high fibre and creatine load
Description: A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Voltage energy bar
Description: A protein bar or control bar consumption after training every day for 5 days, 5 days wash-out, 5 days second bar consumption
Study: NCT02637336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
Study: NCT03657485

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: containing Bifidobacterium breve PB04, Lactobacillus rhamnosus KL53A
Description: we supplemented the probiotic orally during the first hour of life and after 12 hours in mother's milk or formula (the total amount of the probiotic was 2 x 10 6 CFU bacteria).
Study: NCT03908294

Intervention type: DIAGNOSTIC_TEST
Intervention: Lab tests, non-invasive fibrosis (Fibroscan/ARFI)
Description: Patient characteristics, lab values reflecting glucose metabolism and non-invasive fibrosis tests are documented at baseline, during therapy and up to one year after end of treatment.
Study: NCT02637336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: aerobic exercise of moderate intensity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: inhalation of eucalyptus essential oil
Study: NCT03368703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct-current-stimulation
Description: 2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal transcranial direct-current-stimulation
Description: 2mA / 20min Anodal and Sham tDCS over dominant M1. Anodal tDCS consists of 30s of ramp up followed by 20min of stimulation and 30s of ramp down.
Study: NCT03546257

Intervention type: DEVICE
Intervention: magnifying endoscopy with narrow band imaging (ME-NBI)
Description: A system consisting of a magnifying endoscope combined with narrow-band imaging (NBI), with the spectral band width narrowed by optical filters, was developed to enhance visualization of mucosal surface structure and vascular architecture. There were some reports that the magnifying endoscopy with narrow band imaging (ME-NBI) is superior to predict the histologic differentiation, depth of invasion and lesion margin than WLE.
Study: NCT03368703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham transcranial direct-current-stimulation
Description: Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham transcranial direct-current-stimulation
Description: Sham tDCS consists of only 30s of ramp up followed by 30s of ramp down and no further stimulation.~Participants therefore have the same feeling for both modalities : slight itching due to the induced current at the beginning of the protocol (during around 30s) allowing no differentiation by the participant between the anodal or sham sessions.
Study: NCT00116428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVISTAR® THERMOCOOL® Catheter
Description: The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
Study: NCT01438073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kisspeptin 112-121
Description: 24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: Single intravenous dose of GnRH (2.5-250 ng/kg)
Study: NCT03697057

Intervention type: PROCEDURE
Intervention: General anaesthesia
Description: Standard general anaesthesia for gynecologic surgery in patient group
Study: NCT01370668

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional remediation
Description: The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.~The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
Study: NCT04281641

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TCHP
Description: Drug: Trastuzumab 8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV Other Name: Herceptin~Drug: Pertuzumab 840 mg as a loading dose, then 420 mg every 3 weeks, IV Other Name: Perjeta~Drug: carboplatin at target area under the plasma concentration-time curve (AUC) 6~Drug: docetaxel at a starting dose of 75 mg/m2 then to 60mg/m2 (q3w).~All study drugs were administered intravenously.~Procedure: 18-FDG-PET and 68 Ga-Affibody HER-2 Imaging PET will be performed at baseline, on day 15 and before surgery~Genomic alterations (mutations/somatic rearrangements) are detected at baseline, on day 15 and before surgery.
Study: NCT02595359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin intracameral
Study: NCT02713204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN910-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Study: NCT04583566

Intervention type: GENETIC
Intervention: COVID-19 Diagnostic and Assessment Tests
Description: Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.

Intervention type: GENETIC
Intervention: COVID-19 Diagnostic and Assessment Tests
Description: Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.

Intervention type: GENETIC
Intervention: COVID-19 Diagnostic and Assessment Tests
Description: Complete Blood Count (CBC), Differential leukocytes, D-dimer, C-Reactive Protein, Polymerase Chain Reaction (PCR) Test, Ferritin level, Cytokines Profile, Transcriptome Analysis, miRNA Analysis.
Study: NCT02395783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 µg
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 20 µg
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
Study: NCT03501706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequenced Recall of Digits--Auditory
Description: Auditory digit sequence AT memory component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequenced Reverse Recall of Digits--Auditory
Description: Reversed auditory digit sequence AT memory component.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequenced Recall of Words--Visual
Description: Visual word sequence AT memory component